GHK-Cu has been reported in vitro to increase expression of collagen and other matrix proteins, with small topical human cosmetic studies reporting modest measured changes.
What is not established
Human studies are small, short, and frequently industry-sponsored. Injected use is not adequately studied and topical findings do not transfer.
Supporting sources (3)
Effect of a copper tripeptide on postoperative wound healing after carbon dioxide laser resurfacing
Multiple · Archives of Facial Plastic Surgery · 2006 · n = 13
- Population
- Adults following full-face CO2 laser resurfacing
- Endpoint
- Erythema resolution, wrinkle and skin-quality measures
- Route
- Topical
- Quantity as reported
- Topical copper tripeptide formulation
- Frequency
- As specified in the trial protocol
- Duration
- 12 weeks
Result. No significant difference on any objective endpoint. Only subjective patient satisfaction differed.
Adverse events. None significant reported.
Limitations. Thirteen participants, topical, and negative on everything measured objectively. There is no published human trial of injected GHK-Cu at any amount.
GHK-Cu in dermal matrix remodelling and wound-healing research
Multiple (including Pickart and colleagues) · Various dermatology and biochemistry journals · 2022
- Population
- Human fibroblast culture and small topical human studies
- Endpoint
- Collagen synthesis markers, skin density, wrinkle measures
- Route
- Topical in the human work
- Quantity as reported
- Topical formulations at low percentage concentrations
- Frequency
- Varies
- Duration
- 12 weeks
Result. In-vitro work reports increased collagen and matrix protein synthesis. Small topical human cosmetic studies report modest measured changes.
Adverse events. Topical irritation reported in some cosmetic studies.
Limitations. Human evidence is small, often industry-sponsored cosmetic studies with short duration. Topical findings do not transfer to injected use, which is not adequately studied.
Peptide therapeutics in musculoskeletal medicine: a review of the evidence
Multiple · American Journal of Sports Medicine · 2026
- Population
- Review of the published literature on peptides marketed for musculoskeletal use
- Endpoint
- State of the evidence for musculoskeletal indications
Result. Concludes that no clinical data support the use of GHK-Cu for musculoskeletal conditions, that CJC-1295 and ipamorelin synergy data is murine only, that tesamorelin has no supporting orthopaedic evidence, and that for the class generally the indications, amounts, frequency and duration of treatment remain unknown.
Adverse events. Not an outcome of the review.
Limitations. A narrative review, not a meta-analysis. It is catalogued because it is the most recent peer-reviewed statement of how thin this evidence base is, and because it is the counterweight to every vendor page that implies otherwise.
Last evidence review: 2026-08-23